John Strother, MD
Hematology & Oncology · Salem, ORNPI 1518922111
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,267 of the $2,671 with a category attached, or 84.9%. It is spread thinly across 41 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations.
Across 125 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$310
- Pfizer$218
- Novartis$205
- Beone Medicines USA, Inc.$202
- AstraZeneca$162
- Johnson & Johnson$151
- plus $1K from 35 others
Across 220 payments — averaging $2895.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$232K
- GSK$168K
- Janssen Research & Development, LLC$72K
- Incyte Corporation$56K
- Beone Medicines Ltd.$56K
- Eli Lilly$31K
- plus $22K from 3 others
What the payments were for
- Travel & lodging$1676%
- Food & beverage$2,26785%
- Education$2379%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $310 |
| Pfizer | 10 | $218 |
| Novartis | 13 | $205 |
| Beone Medicines USA, Inc. | 5 | $202 |
| AstraZeneca(2 entities) | 8 | $162 |
| Johnson & Johnson | 7 | $151 |
| Amgen | 5 | $129 |
| Merck | 8 | $122 |
| E.r. Squibb & Sons, L.L.C. | 5 | $104 |
| GSK | 4 | $96 |
| Sanofi | 4 | $94 |
| AbbVie | 4 | $84 |
| Jazz Pharmaceuticals Inc. | 3 | $76 |
| Lilly USA, LLC | 4 | $68 |
| Gilead(2 entities) | 4 | $66 |
| Seagen Inc. | 3 | $53 |
| Bristol Myers Squibb | 2 | $49 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Taiho Oncology, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Myovant Sciences Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Clovis Oncology, Inc. | 1 | $19 |
| Tesaro, Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Incyte Corporation | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
How this compares
$2,671 in reported general payments places this provider in the 70th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 29 | $549,366 |
| IbrancePalbociclib | 41 | $528,914 |
| Lenalidomide | 47 | $490,678 |
| BrukinsaZanubrutinib | 35 | $484,362 |
| ImbruvicaIbrutinib | 25 | $404,006 |
| TagrissoOsimertinib Mesylate | 18 | $383,694 |
| PomalystPomalidomide | 14 | $370,344 |
| CalquenceAcalabrutinib Maleate | 22 | $363,894 |
| VerzenioAbemaciclib | 23 | $345,301 |
| StivargaRegorafenib | 16 | $332,656 |
| FruzaqlaFruquintinib | 13 | $315,680 |
| VenclextaVenetoclax | 22 | $303,871 |
| JakafiRuxolitinib Phosphate | 16 | $269,762 |
| RevlimidLenalidomide | 13 | $224,995 |
| XtandiEnzalutamide | 13 | $164,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $162 | $747,58740 claims |
| PfizerIbrance, Inlyta, Eliquis | $218 | $725,919123 claims |
| NovartisTasigna | $205 | $549,36629 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $104 | $370,34414 claims |
| Lilly USA, LLCVerzenio | $68 | $345,30123 claims |
| BayerStivarga | $14 | $332,65616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $28 | $315,68013 claims |
| AbbVieVenclexta | $84 | $303,87122 claims |
| Incyte CorporationJakafi | $14 | $269,76216 claims |
| Bristol Myers SquibbRevlimid | $49 | $224,99513 claims |
| Astellas Pharma US IncXtandi | $310 | $164,18013 claims |
| Johnson & JohnsonXarelto | $151 | $13,31315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Salem
- William PierceSalem$9K
- Janelle MeyerSalem$6K
- Renee PrinsSalem$2K
- Nicholas BarberSalem$1K
- Rahim JiwaniSalem$1K
- Charles PetruninSalem$961
- Brian DrukerPortland$1.9M
- Bo WangCorvallis$251K
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.